RT @UMCGlobalSafety: "#Pharmacovigilance is still a relatively new concept with low priority in dev. countries, although various issues are…
RT @UMCGlobalSafety: "#Pharmacovigilance is still a relatively new concept with low priority in dev. countries, although various issues are…
RT @UMCGlobalSafety: "#Pharmacovigilance is still a relatively new concept with low priority in dev. countries, although various issues are…
RT @UMCGlobalSafety: "#Pharmacovigilance is still a relatively new concept with low priority in dev. countries, although various issues are…
RT @UMCGlobalSafety: "#Pharmacovigilance is still a relatively new concept with low priority in dev. countries, although various issues are…
RT @UMCGlobalSafety: "#Pharmacovigilance is still a relatively new concept with low priority in dev. countries, although various issues are…
RT @UMCGlobalSafety: "#Pharmacovigilance is still a relatively new concept with low priority in dev. countries, although various issues are…
"#Pharmacovigilance is still a relatively new concept with low priority in dev. countries, although various issues are raising concerns that magnify the need for systems to monitor post marketing #DrugSafety." Read more in IJCP: https://t.co/CTo6gmgVTP &am
RT @UMCGlobalSafety: We shared the first part of "#Pharmacovigilance in developing countries" from IJCP a couple fo days ago – here is part…
RT @UMCGlobalSafety: We shared the first part of "#Pharmacovigilance in developing countries" from IJCP a couple fo days ago – here is part…
RT @UMCGlobalSafety: We shared the first part of "#Pharmacovigilance in developing countries" from IJCP a couple fo days ago – here is part…
We shared the first part of "#Pharmacovigilance in developing countries" from IJCP a couple fo days ago – here is part II, focusing on the path forward: https://t.co/TCIhEKiWOj #patientsafety https://t.co/dSW1NLw6LF